ACHL

Achilles Therapeutics plc (ACHL) | Rumor.io

Achilles Therapeutics

ACHL

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ACHL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 4

Achillies Therapeutics plc ($ACHL) has announced a members' voluntary liquidation to return capital to shareholders after a strategic review and asset sale.
The company expects to return $1.50 to $1.66 per share to shareholders, 6-8 weeks after March 20, following the liquidation.
The liquidation has caused the stock price to drop, with some investors advising to cut losses and preserve remaining funds, while others criticize the company's handling of the situation.

Generated by AI

Sentiment

Of the messages about ACHL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75% +9.58
Bearish	—	—	—	25% -9.58

Bullish· Sep 19

Achilles Therapeutics is ditching its TIL programs and licensing promising mAb drugs, which could lead to significant growth.
The company's strong cash position of $95.1M and refocusing on partnerships and strategic alternatives are driving its stock up by 36%.
The stock's uptrend and strong momentum, with a 46% increase, suggest that it is a promising investment opportunity.

Bearish· Feb 4

The company, Achilles Therapeutics plc, has decided to liquidate and return cash to shareholders, with an expected return of $1.50 to $1.66 per share.
The liquidation of the company is a result of a significant decline in the stock price since its IPO in 2021, with the price dropping by over 90% to its current level.
The company's decision to liquidate and return cash may have been a late move, as the directors resigned and the company sold its assets to AstraZeneca in December, and the Chief Scientific Officer has also resigned.

Generated by AI

Topics

Of the messages about ACHL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Sep 19

Achilles Therapeutics plc has discontinued its TIL-based cNeT therapy program and closed the Phase I/IIa CHIRON and THETIS clinical trials due to lack of commercial viability.
The company will refocus on exploring partnerships with third parties developing alternative modalities targeting clonal neoantigens for cancer treatment and has engaged BofA Securities to advise on value-maximizing strategies.
As part of its strategic update, Achilles Therapeutics will implement a workforce reduction and cost-cutting measures, with a cash position of $95.1 million as of June 30, 2024.

Generated by AI

Community

Of the messages about ACHL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	42.47%
Newcomers	—	—	—	57.53%

Regulars· Sep 19

Achilles Therapeutics has discontinued development of its TIL-based cNeT therapy, and its cash position is around $95M.
The company's stock has seen a significant increase in value, with a 46% gain, and is being considered as a blueprint for other distressed biotechs.
The company is exploring strategic alternatives, including licensing its promising mAb drugs, and has a cash position that could be used for acquisitions or partnerships.

Newcomers· Feb 4

New investors are excited about Achilles Therapeutics plc's proposed voluntary liquidation, with expected returns of $1.50-$1.66 per share.
The distribution is lower than some newcomers' initial calculations, but a 40% return in just 3 months is considered a good outcome.
Some investors are holding onto their shares, citing a 24% increase in price to $1.41, and are hopeful that the company's difficulties have been addressed.

Generated by AI

Also Discussed

Investors talking about ACHL also mention

#	Name	Attention
1	KRON - Kronos Bio, Inc.	——
2	ImageneBio, Inc.IKNA	0%0
3	Instil Bio Inc.TIL	0%0
4	FRLN - Freeline Therapeutics Holdings plc	——
5	EFTR - eFFECTOR Therapeutics, Inc.	——
6	RPHM - Reneo Pharmaceuticals, Inc.	——
7	TLIS - Talis Biomedical Corporation	——
8	IM Cannabis Corp.IMCC	0%+0
9	PMV Pharmaceuticals, Inc.PMVP	0%0
10	Dermata Therapeutics, Inc.DRMA	0%new